.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Dow
McKinsey
Accenture
Boehringer Ingelheim
Merck
Medtronic
Daiichi Sankyo
Colorcon
McKesson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,822,490

« Back to Dashboard

Which drugs does patent 8,822,490 protect, and when does it expire?


Patent 8,822,490 protects RELISTOR and is included in one NDA. There have been three Paragraph IV challenges on Relistor.

This patent has twenty-eight patent family members in fifteen countries.

Summary for Patent: 8,822,490

Title:Peripheral opioid receptor antagonists and uses thereof
Abstract: The present invention provides a compound of formula I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s): Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (East Hanover, NJ), Szeliga; Jan (Croton On Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:13/875,657
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes► Subscribe► SubscribeYTREATMENT OF OPIOID-INDUCED CONSTIPATION► Subscribe
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-001Apr 24, 2008RXYesYes► Subscribe► SubscribeYTREATMENT OF OPIOID-INDUCED CONSTIPATION► Subscribe
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-003Sep 27, 2010RXYesYes► Subscribe► SubscribeYTREATMENT OF OPIOID-INDUCED CONSTIPATION► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,822,490

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,492,445Peripheral opioid receptor antagonists and uses thereof► Subscribe
8,247,425Peripheral opioid receptor antagonists and uses thereof► Subscribe
9,724,343Peripheral opioid receptor antagonists and uses thereof► Subscribe
9,180,125Peripheral opioid receptor antagonists and uses thereof► Subscribe
8,455,644Peripheral opioid receptor antagonists and uses thereof► Subscribe
8,420,663Peripheral opioid receptor antagonists and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,822,490

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China105399673► Subscribe
European Patent Office2356119► Subscribe
Hong Kong1199442► Subscribe
Israel211865► Subscribe
Israel229507► Subscribe
Japan2012504635► Subscribe
Japan5719773► Subscribe
Japan2015129144► Subscribe
Japan2017101053► Subscribe
South Korea20110060967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
AstraZeneca
Moodys
Chinese Patent Office
McKinsey
Cantor Fitzgerald
Accenture
Teva
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot